Imperial College London
Portrait Picture

MrMikaelSodergren

Faculty of Medicine, Department of Surgery & Cancer

Clinical Senior Lecturer in Hepatopancreatobiliary Surgery
 
 
 
//

Contact

 

m.sodergren

 
 
//

Location

 

BN2/13Block B Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Nicholas:2023:10.1080/14737175.2023.2174017,
author = {Nicholas, M and Erridge, S and Bapir, L and Pillai, M and Dalavaye, N and Holvey, C and Coomber, R and Rucker, JJ and Weatherall, MW and Sodergren, MH},
doi = {10.1080/14737175.2023.2174017},
journal = {Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders},
pages = {1--12},
title = {UK medical cannabis registry: assessment of clinical outcomes in patients with headache disorders},
url = {http://dx.doi.org/10.1080/14737175.2023.2174017},
volume = {23},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - ObjectivesHeadache disorders are a common cause of disability and reduced health-related quality of life globally. Growing evidence supports the use of cannabis-based medicinal products (CBMPs) for chronic pain; however, a paucity of research specifically focuses on CBMPs’ efficacy and safety in headache disorders. This study aims to assess changes in validated patient-reported outcome measures (PROMs) in patients with headaches prescribed CBMPs and investigate the clinical safety in this population.MethodsA case series of the UK Medical Cannabis Registry was conducted. Primary outcomes were changes from baseline in PROMs (Headache Impact Test-6 (HIT-6), Migraine Disability Assessment (MIDAS), EQ-5D-5L, Generalized Anxiety Disorder-7 (GAD-7) questionnaire and Single-Item Sleep Quality Scale (SQS)) at 1-, 3-, and 6-months follow-up. P-values <0.050 were deemed statistically significant.ResultsNinety-seven patients were identified for inclusion. Improvements in HIT-6, MIDAS, EQ-5D-5L and SQS were observed at 1-, 3-, and 6-months (p < 0.005) follow-up. GAD-7 improved at 1- and 3-months (p < 0.050). Seventeen (17.5%) patients experienced a total of 113 (116.5%) adverse events.ConclusionImprovements in headache/migraine-specific PROMs and general health-related quality of life were associated with the initiation of CBMPs in patients with headache disorders. Cautious interpretation of results is necessary, and randomized control trials are required to ascertain causality.
AU  - Nicholas,M
AU  - Erridge,S
AU  - Bapir,L
AU  - Pillai,M
AU  - Dalavaye,N
AU  - Holvey,C
AU  - Coomber,R
AU  - Rucker,JJ
AU  - Weatherall,MW
AU  - Sodergren,MH
DO  - 10.1080/14737175.2023.2174017
EP  - 12
PY  - 2023///
SN  - 1473-7175
SP  - 1
TI  - UK medical cannabis registry: assessment of clinical outcomes in patients with headache disorders
T2  - Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders
UR  - http://dx.doi.org/10.1080/14737175.2023.2174017
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000925502900001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.tandfonline.com/doi/full/10.1080/14737175.2023.2174017
UR  - http://hdl.handle.net/10044/1/103156
VL  - 23
ER  -
Download